Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CAPS2 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, IF, E |
|---|---|
| Primary Accession | Q86UW7 |
| Other Accession | NP_060424, 148839294 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 138, 145 kDa Observed: 150 kDa |
| Application Notes | CAPS2 antibody can be used for detection of CAPS2 by Western blot at 0.5 - 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL. |
| Gene ID | 93664 |
|---|---|
| Target/Specificity | CADPS2; Multiple isoforms of CAPS2 are known to exist. This CAPS2 antibody is predicted to be specific to CAPS2 and not recognize CAPS1. |
| Reconstitution & Storage | CAPS2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | CAPS2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CADPS2 |
|---|---|
| Synonyms | CAPS2, KIAA1591 |
| Function | Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates neurotrophin release from granule cells leading to regulate cell differentiation and survival during cerebellar development. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles (By similarity). |
| Cellular Location | Cytoplasmic vesicle membrane; Peripheral membrane protein; Cytoplasmic side. Synapse. Note=Membrane-associated to vesicles. Strongly enriched in synaptic fractions. Probably localizes to different vesicles compared to CADPS. Enriched on vesicular structures in the parallel fiber terminal of granule cells that are distinct from synaptic vesicles |
| Tissue Location | Widely expressed. Expressed in all adult and fetal tissues examined, with the strongest expression in kidney and pancreas In brain, it is expressed at high levels in cerebellum, to a lesser degree in cerebral cortex, occipital pole, and frontal and temporal lobes. Only weakly expressed in medulla, spinal cord and putamen |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CAPS2 Antibody: CAPS2 and the related protein CAPS1 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficient neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. Like CAPS1, numerous isoforms of CAPS2 are known to exist. These isoforms show distinct expression patterns in the brain. For example, CAPS2b showed high expression in the developing cerebellum. Furthermore, one version of CAPS2 mRNA that lacks exon 3 is detected in some autistic patients, suggesting that the differential expression pattern of CAPS2 is involved in neuronal development.
References
Walent JH, Porter BW, and Martin TF. A novel 145 kD brain cytosolic protein reconstitutes Ca(2+)-regulated secretion in permeable neuroendocrine cells. Cell 1992; 70:765-775.
Juckusch WJ, Speidel D, Sigler A, et al. CAPS-1 and CAPS-2 are essential synaptic vesicle priming proteins. Cell 2007; 131:796-808.
Sadakata T, Washida M, and Furuichi T. Alternative splicing variants in mouse CAPS2: differential expression and functional properties of splicing variants. BMC Neurosci. 2007; 8:25-35.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
